{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:34:53Z","timestamp":1789644893446,"version":"4.0.0"},"reference-count":57,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T00:00:00Z","timestamp":1759622400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Lupus Accelerating Breakthroughs Consortium","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2025,9,2]]},"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:p>Early data have shown the potential of chimeric antigen receptor (CAR) T-cell therapies to expand the therapeutic landscape in systemic lupus erythematosus (SLE). While many CAR T-cell therapy learnings can be drawn from the experience of this modality in oncology, key questions remain regarding clinical development considerations unique to lupus. To assess and discuss these issues, the Lupus Accelerating Breakthroughs Consortium, a public\u2013private partnership, convened a multi-partner working group to collect the diverse perspectives of academics\/clinicians (including rheumatologists and oncologists), industry representatives (including SLE as well as CAR T-cell clinical development experts), regulators and people living with lupus on this potentially ground-breaking therapy. The working group considered the risk\/benefit considerations for eligibility criteria in lupus, early-phase dosing and dose-limiting toxicity challenges, incorporation of comparator arms in late-phase registrational trial design, SLE-specific issues in conditioning therapy and immune monitoring and the limitations of SLE pre-clinical models for studying cell therapies. The key future \u2018calls to action\u2019 for the field include the need for well-defined severity\/refractoriness-based eligibility criteria, the need for long-term monitoring infrastructure and the need for educational and logistical support for rheumatologists and patients.<\/jats:p>","DOI":"10.1136\/rmdopen-2025-005866","type":"journal-article","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T06:35:22Z","timestamp":1759732522000},"page":"e005866","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Key considerations for advancing chimeric antigen receptor (CAR) T-cell therapy for systemic lupus erythematosus (SLE): a multi-partner\/disciplinary working group perspective"],"prefix":"10.1136","volume":"11","clinical-trial-number":[{"clinical-trial-number":"nct06465147","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06839976","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct06308978","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Elena W Y","family":"Hsieh","sequence":"first","affiliation":[{"name":"Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B","family":"Chung","sequence":"additional","affiliation":[{"name":"Amgen Inc, Thousand Oaks, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afsah","family":"Amin","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca D","family":"Askanase","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrix","family":"Bartok","sequence":"additional","affiliation":[{"name":"Gilead Sciences Inc, Foster City, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Brunetta","sequence":"additional","affiliation":[{"name":"Sana Biotechnology Inc, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene J","family":"Carrasco-Alfonso","sequence":"additional","affiliation":[{"name":"AstraZeneca, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy","family":"Coney","sequence":"additional","affiliation":[{"name":"Lupus Voices Council, Lupus Research Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer C","family":"Cooper","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Dall\u2019Era","sequence":"additional","affiliation":[{"name":"University of California San Francisco, San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolay","family":"Delev","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Co, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eldred","sequence":"additional","affiliation":[{"name":"AbbVie Inc, North Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard A","family":"Furie","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Northwell Health, Great Neck, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Garces","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Co, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Groover","sequence":"additional","affiliation":[{"name":"Michigan Lupus Foundation, Traverse City, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Harrington","sequence":"additional","affiliation":[{"name":"Fluent in Science, LLC, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan J","family":"Hogan","sequence":"additional","affiliation":[{"name":"Cabaletta Bio Inc, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin H","family":"Imperato","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0673-6402","authenticated-orcid":false,"given":"Meredith","family":"Jackson","sequence":"additional","affiliation":[{"name":"Lupus Research Alliance, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaun W","family":"Jackson","sequence":"additional","affiliation":[{"name":"Center for Immunity and Immunotherapies, Seattle Children\u2019s Research Institute, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Artemio M","family":"Jongco","sequence":"additional","affiliation":[{"name":"GlaxoSmithKline, Philadelphia, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine","family":"Karis","sequence":"additional","affiliation":[{"name":"Nkarta Inc, South San Francisco, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Koegel","sequence":"additional","affiliation":[{"name":"Bristol Myers Squibb Co, Princeton, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian F","family":"K\u00f6nig","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Medicine, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"},{"name":"Ludwig Center, Johns Hopkins Medicine Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Koretzky","sequence":"additional","affiliation":[{"name":"Cornell University, Ithaca, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay","family":"Kumar","sequence":"additional","affiliation":[{"name":"Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9507-3338","authenticated-orcid":false,"given":"Eric","family":"Morand","sequence":"additional","affiliation":[{"name":"School of Clinical Sciences, Monash University, Clayton, Victoria, Australia"},{"name":"Monash Health, Clayton, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimee S","family":"Payne","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaishali","family":"Popat","sequence":"additional","affiliation":[{"name":"Center for Biologics Research and Evaluation, US Food and Drug Administration, Silver Spring, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiyer","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Synthekine Inc, Menlo Park, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Rohan","sequence":"additional","affiliation":[{"name":"Division of Allergy, Immunology, and Transplantation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[{"name":"Columbia University Irving Medical Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Schett","sequence":"additional","affiliation":[{"name":"Department of Medicine 3-Rheumatology and Immunology and Deutshes Zentrum Immuntherapie, Friedrich-Alexander-Universitat Erlangen-Nurnberg, Erlangen, BY, Germany"},{"name":"Universitatsklinikum Erlangen, Erlangen, BY, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aman P","family":"Singh","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals America Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6438-8663","authenticated-orcid":false,"given":"Ronald F","family":"van Vollenhoven","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Amsterdam University Medical Center, Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra","family":"Zack","sequence":"additional","affiliation":[{"name":"Fate Therapeutics Inc, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,10,5]]},"reference":[{"key":"2026010700550921000_11.4.e005866.1","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1038\/s41577-024-01035-3","article-title":"Chimeric antigen receptor T cell therapy for autoimmune disease","volume":"24","author":"Chung","year":"2024","journal-title":"Nat Rev Immunol"},{"key":"2026010700550921000_11.4.e005866.2","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z"},{"key":"2026010700550921000_11.4.e005866.3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026010700550921000_11.4.e005866.4","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","article-title":"CAR T-cell therapy in autoimmune diseases","volume":"402","author":"Schett","year":"2023","journal-title":"The Lancet"},{"key":"2026010700550921000_11.4.e005866.5","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/s41584-025-01247-4","article-title":"Lupus ABC spearheading a new era of collaboration to advance lupus drug development","volume":"21","author":"Nguyen","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"2026010700550921000_11.4.e005866.6","first-page":"1122","article-title":"A critical review of clinical trials in systemic lupus erythematosus","volume":"25","author":"Mahieu","year":"2016","journal-title":"Lupus (Los Angel)"},{"key":"2026010700550921000_11.4.e005866.7","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2023-001114","article-title":"Clinical trial outcomes for SLE: what we have and what we need","volume":"11","author":"Arnaud","year":"2024","journal-title":"Lupus Sci Med"},{"key":"2026010700550921000_11.4.e005866.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2022.152010"},{"key":"2026010700550921000_11.4.e005866.9","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2015-000136","article-title":"Development and validation of a simple lupus severity index using ACR criteria for classification of SLE","volume":"3","author":"Bello","year":"2016","journal-title":"Lupus Sci Med"},{"key":"2026010700550921000_11.4.e005866.10","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2026010700550921000_11.4.e005866.11","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-cell therapy: Full speed ahead","volume":"37 Suppl 1","author":"Sermer","year":"2019","journal-title":"Hematol Oncol"},{"key":"2026010700550921000_11.4.e005866.12","unstructured":"Seattle children\u2019s launches first u.s. car t-cell clinical trial. Seattle Child. n.d. Available: https:\/\/www.seattlechildrens.org\/healthy-tides\/first-us-car-t-cell-clinical-trial-for-children-with-lupus\/"},{"key":"2026010700550921000_11.4.e005866.13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12969-024-00990-4","article-title":"CAR T cell therapy for refractory pediatric systemic lupus erythematosus: a new era of hope?","volume":"22","author":"Stojkic","year":"2024","journal-title":"Pediatr Rheumatol"},{"key":"2026010700550921000_11.4.e005866.14","unstructured":"Nesbitt H . American society of nephrology | kidney week - abstract details. 2024. Available: https:\/\/www.asn-online.org\/education\/kidneyweek\/2024\/program-abstract.aspx?controlId=4176125 [Accessed 2 Dec 2024]."},{"key":"2026010700550921000_11.4.e005866.15","unstructured":"Pan J . Open-Label, Non-Randomized, Single-Arm, Phase 1\/2 Study of Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus. ClinicaltrialsGov 2024."},{"key":"2026010700550921000_11.4.e005866.16","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.220513"},{"key":"2026010700550921000_11.4.e005866.17","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(19)30142-0"},{"key":"2026010700550921000_11.4.e005866.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221295"},{"key":"2026010700550921000_11.4.e005866.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.12.017"},{"key":"2026010700550921000_11.4.e005866.20","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142"},{"key":"2026010700550921000_11.4.e005866.21","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature New Biol"},{"key":"2026010700550921000_11.4.e005866.22","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.omtm.2018.01.010","article-title":"The Pharmacology of T Cell Therapies","volume":"8","author":"Milone","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"2026010700550921000_11.4.e005866.23","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cpt.2986","article-title":"Best Practices and Considerations for Clinical Pharmacology and Pharmacometric Aspects for Optimal Development of CAR-T and TCR-T Cell Therapies: An Industry Perspective","volume":"114","author":"Mody","year":"2023","journal-title":"Clin Pharmacol Ther"},{"key":"2026010700550921000_11.4.e005866.24","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24065688","article-title":"CAR T-Cell Persistence Correlates with Improved Outcome in Patients with B-Cell Lymphoma","volume":"24","author":"Wittibschlager","year":"2023","journal-title":"Int J Mol Sci"},{"key":"2026010700550921000_11.4.e005866.25","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-225785"},{"key":"2026010700550921000_11.4.e005866.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.478"},{"key":"2026010700550921000_11.4.e005866.27","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00119-3"},{"key":"2026010700550921000_11.4.e005866.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209519"},{"key":"2026010700550921000_11.4.e005866.29","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-023-00993-7"},{"key":"2026010700550921000_11.4.e005866.30","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S242097"},{"key":"2026010700550921000_11.4.e005866.31","unstructured":"Research C for DE and . Considerations for the design and conduct of externally controlled trials for drug and biological products. 2023. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-design-and-conduct-externally-controlled-trials-drug-and-biological-products"},{"key":"2026010700550921000_11.4.e005866.32","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41591-025-03718-3","article-title":"BCMA CAR T cells in a patient with relapsing idiopathic inflammatory myositis after initial and repeat therapy with CD19 CAR T cells","volume":"31","author":"M\u00fcller","year":"2025","journal-title":"Nat Med"},{"key":"2026010700550921000_11.4.e005866.33","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.jtct.2023.04.007","article-title":"Mechanisms of Resistance and Treatment of Relapse after CAR T-cell Therapy for Large B-cell Lymphoma and Multiple Myeloma","volume":"29","author":"Rejeski","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"2026010700550921000_11.4.e005866.34","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2021.1894648","article-title":"Resistance to CART cell therapy: lessons learned from the treatment of hematological malignancies","volume":"62","author":"Sakemura","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2026010700550921000_11.4.e005866.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0184-6"},{"key":"2026010700550921000_11.4.e005866.36","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac108"},{"key":"2026010700550921000_11.4.e005866.37","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/j.immuni.2024.10.011","article-title":"CAR T cells in autoimmune disease: On the road to remission","volume":"57","author":"Schett","year":"2024","journal-title":"Immunity"},{"key":"2026010700550921000_11.4.e005866.38","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1158\/2643-3230.BCD-22-0067","article-title":"CAR T-cell Therapy Meets Clonal Hematopoiesis","volume":"3","author":"Uslu","year":"2022","journal-title":"Blood Cancer Discov"},{"key":"2026010700550921000_11.4.e005866.39","unstructured":"N.d. Long Term Follow-Up After Administration of Human Gene Therapy Products; Guidance for Industry."},{"key":"2026010700550921000_11.4.e005866.40","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1303935","article-title":"Lymphodepletion - an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle","volume":"14","author":"Lickefett","year":"2023","journal-title":"Front Immunol"},{"key":"2026010700550921000_11.4.e005866.41","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V126.23.4426.4426","article-title":"Cyclophosphamide and Fludarabine Conditioning Chemotherapy Induces a Key Homeostatic Cytokine Profile in Patients Prior to CAR T Cell Therapy","volume":"126","author":"Bot","year":"2015","journal-title":"Blood"},{"key":"2026010700550921000_11.4.e005866.42","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41409-025-02539-9","article-title":"Lymphodepletion chemotherapy in chimeric antigen receptor-engineered T (CAR-T) cell therapy in lymphoma","volume":"60","author":"Canelo-Vilaseca","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026010700550921000_11.4.e005866.43","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"2026010700550921000_11.4.e005866.44","unstructured":"Goulding J , Reiser J , O\u2019Connor A , et al . Development of next generation car t cell therapy for the off-the-shelf treatment of autoimmune diseases without conditioning chemotherapy. ACR Meet. Abst. Available: https:\/\/acrabstracts.org\/abstract\/development-of-next-generation-car-t-cell-therapy-for-the-off-the-shelf-treatment-of-autoimmune-diseases-without-conditioning-chemotherapy\/ [Accessed 27 Jan 2025]."},{"key":"2026010700550921000_11.4.e005866.45","unstructured":"Fate therapeutics presents 6-month follow-up data on first patient treated in phase 1 autoimmunity study with fludarabine-free conditioning and ft819 off-the-shelf, 1xx car t-cell product candidate at acr convergence | fate therapeutics, inc. Available: https:\/\/ir.fatetherapeutics.com\/news-releases\/news-release-details\/fate-therapeutics-presents-6-month-follow-data-first-patient [Accessed 27 Jan 2025]."},{"key":"2026010700550921000_11.4.e005866.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.10.007"},{"key":"2026010700550921000_11.4.e005866.47","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/art.40079","article-title":"Brief Report: The Euro\u2010Lupus Low\u2010Dose Intravenous Cyclophosphamide Regimen Does Not Impact the Ovarian Reserve, as Measured by Serum Levels of Anti\u2013M\u00fcllerian Hormone","volume":"69","author":"Tamirou","year":"2017","journal-title":"Arthritis & Rheumatology"},{"key":"2026010700550921000_11.4.e005866.48","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/j.jtct.2022.06.002","article-title":"Fertility and CAR T-cells: Current practice and future directions","volume":"28","author":"Ligon","year":"2022","journal-title":"Transplant Cell Ther"},{"key":"2026010700550921000_11.4.e005866.49","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility Preservation in People With Cancer: ASCO Guideline Update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"key":"2026010700550921000_11.4.e005866.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.3288"},{"key":"2026010700550921000_11.4.e005866.51","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01342"},{"key":"2026010700550921000_11.4.e005866.52","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1038\/s41577-025-01141-w","article-title":"Defining immune reset: achieving sustained remission in autoimmune diseases","volume":"25","author":"Junt","year":"2025","journal-title":"Nat Rev Immunol"},{"key":"2026010700550921000_11.4.e005866.53","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02017-5"},{"key":"2026010700550921000_11.4.e005866.54","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight"},{"key":"2026010700550921000_11.4.e005866.55","doi-asserted-by":"crossref","first-page":"271694","DOI":"10.1155\/2011\/271694","article-title":"Murine Models of Systemic Lupus Erythematosus","volume":"2011","author":"Perry","year":"2011","journal-title":"Biomed Res Int"},{"key":"2026010700550921000_11.4.e005866.56","doi-asserted-by":"publisher","DOI":"10.1002\/art.30424"},{"key":"2026010700550921000_11.4.e005866.57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-16999-7","article-title":"A Novel Human Systemic Lupus Erythematosus Model in Humanised Mice","volume":"7","author":"Gunawan","year":"2017","journal-title":"Sci Rep"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2025-005866","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:55:25Z","timestamp":1767776125000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2025-005866"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,10,5]]},"published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1136\/rmdopen-2025-005866"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2025-005866","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]}}}